
Haemonetics (HAE) Stock Forecast & Price Target
Haemonetics (HAE) Analyst Ratings
Bulls say
Haemonetics is a leader in the medical products and solutions industry, with innovative technologies and a strong global presence. Its two core business units, Apheresis and MedSurg, are poised for continued growth and profitability. While there have been some recent commercial execution challenges, the company is taking steps to address these and has a solid track record of successful acquisitions. With a stable Plasma business and a recovery in its IVT segment, HAE has the potential to reach best-in-class margins among its peers.
Bears say
Haemonetics is a company that operates in a competitive market, with its blood center segment facing challenges due to high competition. While the approval of Vascade MVP XL label expansion and pending FDA review for PerQseal Elite are positive developments, the company's guidance for FY27 shows only modest growth potential. With a decline in the blood center segment and a conservative outlook, Haemonetics may struggle to meet expectations, leading to a negative outlook from a financial analysis perspective.
This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.
Haemonetics (HAE) Analyst Forecast & Price Prediction
Start investing in Haemonetics (HAE)
Order type
Buy in
Order amount
Est. shares
0 shares